Clinical potential of minocycline for schizophrenia
| Project/Area Number |
20591366
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Shimane University |
|---|
Principal Investigator |
MIYAOKA Tsuyoshi Shimane University, 医学部, 准教授 (50284047)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 統合失調症 / ミノサイクリン / 抗精神病薬作用 / 統合失調症モデルラット / 塩酸ミノサイクリン / 神経保護作用 / 臨床研究 / 動物実験 |
|---|
| Research Abstract |
Clinical potential of minocycline for schizophrenia
Minocycline, an antibiotic of the tetracycline family, has been shown to display neurorestorative or neuroprotective properties in various models of neurodegenerative diseases. Despite controversies about its efficacy, the relative safety and tolerability of minocycline have led to various clinical trials. In our study, we administered minocycline as an open label adjunct to anitipsychotic medication to patients with schizophrenia. And also I assessed the effects of antipsychotics and minocycline on schizophrenia animal model. The results of these trial suggested that minocycline might be a safe and effective adjunct to antipsychotic medications, and that augmentation with minocycline may prove to be a viable strategy for "boosting" antipsychotic efficacy and for treating schizophrenia.
|
Report
(4 results)
Research Products
(17 results)
